Revance Therapeutics Inc(RVNC) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI) which competed phase 3 clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; in phase 2 clinical trials to treat adult upper limb spasticity and plantar fasciitis, and in pre-clinical trials to treat chronic migraine. It is also developing DAXI for forehead lines, lateral canthal lines, and upper facial lines that is in phase 2 clinical trials; DaxibotulinumtoxinA Topical for therapeutic and aesthetic applications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration agreement with Mylan Ireland Limited for the development, manufacture, and commercialization of a biosimilar to BOTOX; and collaboration and license agreement with Mylan N.V. for the development and regulatory approval of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.

Current Price

$28.48

RSI

52.082

Beta:

1.292333

February 25, 2021
333.6M
183.2M
-64.5M

12408.989 %
-78.769 %
-38.555 %

$15,325,000
$413,000
$3,729,000
$262,000
$300,000
$300,000
3610.654 %
-802.906 %
1323.282 %
-14.504 %
0.000 %

$-284,709,000
$-159,429,000
$-139,568,000
$-120,587,000
$-89,270,000
$-73,476,000
-44.003 %
-12.458 %
-13.600 %
-25.970 %
-17.692 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.